BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors
Updated Phase 1 clinical data are expected in the second half of 2026
https://finance.yahoo.com/sectors/healthcare/articles/bbot-granted-u-fda-fast-200600124.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.